TheEdgeResearch
Home / Stocks / TLTFF

Theralase Technologies Inc. (TLTFF)

OTC Healthcare Medical - Devices
$0.12 ▲ +0.00%
Market Cap
$37.3M
Sector
Healthcare
Industry
Medical - Devices
Beta
0.59
52-Wk Range
0.048-0.31
CEO
Roger J. Dumoulin-White
Country
CA
Currency
USD

Theralase Technologies Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $0.12, up 0.00% on the session, giving a market capitalisation of $37.3M. On trailing twelve-month figures it carries a trailing P/E of -12.32, a net margin of -472.5%. Its beta of 0.59 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-12.32
Price / Sales
67.71
Price / Book
7.26
EV / EBITDA
-13.94
Gross margin
44.2%
Operating margin
-474.3%
Net margin
-472.5%
Return on equity
—
Debt / equity
0.02
Current ratio
5.48
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
14
IPO date
2010-04-05
Headquarters
Toronto, ON, CA
About Theralase Technologies Inc.

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has a collaboration with the National Microbiology Laboratory, a Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. Theralase Technologies Inc. is based in Toronto, Canada.

More research on TLTFF
TLTFF technical analysis TLTFF TheEdge Score Compare against peers
Open full interactive analysis & DCF →